Camurus' hormone disorder drug expected to be approved in 2027 after fresh FDA setback
Camurus announces expansion of Lilly collaboration
Camurus AB (publ) (CAMRF) Q1 2026 Earnings Call Transcript
Camurus AB (publ) (CAMRF) Q4 2025 Earnings Call Transcript
Camurus AB (publ) (CAMRF) Q3 2025 Earnings Call Transcript
Camurus and Lilly enter collaboration and license agreement for long-acting FluidCrystal® incretins
US FDA declines to approve Camurus' rare hormone disorder drug
New publication shows effectiveness data for weekly and monthly buprenorphine injections in treating opioid dependence in individuals using fentanyl